Regulatory framework and disparities of complex generics in United States,European Union & Latin America

Introduction

The pharmaceuticals are divided as: small molecule drugs, complex drugs and biologics. The drug products can be either innovator product or its generic version. In case of simple generic drug products, the market opportunities are abating along with price reduction. This is due to ever-growing competition within the distribution system or channel all over the world, especially in the regulated markets. Thus, the drug manufacturers are inclined towards the development of complex generics rather than the simple generics Due to some competition, the market for complicated generics is highly valuable. The market for complex generics is currently less competitive. Many complex products patents and exclusivities are about to expire in these areas, which has strengthened the market for generic versions of these products ¹ While regulatory guidance for authorization of generic versions of small molecule drugs is well established, guidance for complex drug products is still evolving. Although they differ from biologic products, complex drugs are constructed of huge, extremely complex, and synthetic components. The complex drug landscape is visualized in Figure 1

OPEN IN VIEWER

Figure 1.

The complex drug landscape.

Drug goods are positioned based on the difficulty of determining the pharmaceutical and bioequivalence of two different therapeutic products (i.e., the reference product and its generic version). Orange represents conventional low-molecular-weight medications that can be thoroughly defined; PE and BE are reasonably easy to demonstrate. Green is used to represent biologics; PE and BE demonstration is a little trickier. Complex drugs are shown in blue (NBCDs) or white (other complex drugs). For the majority of NBCDs, both PE and BE are difficult to demonstrate, owing to the inability to synthesize homo-molecular material, an unknown mode of action, and/or the difficulty to fully characterize the products. Albumin bound nanoparticles and low-molecular weight heparins are blue with a green outline (classification of these drugs varies across the globe).

In Europe and certain other parts of the world, biologics are items that are utilised in the diagnosis, treatment, and prevention of disease. They are often created utilising biological organisms or from live materials like cells or tissues. Analogous to generic versions of small molecule drugs, copy versions of biologics that have successfully undergone a rigorous comparability program are referred to as “biosimilar;” In terms of their effectiveness, safety, biological activity, and quality, they are very comparable to another biologic drug and many have already been approved by regulatory authorities.

The active ingredient in NBCDs is not a homo-molecular structure but rather a mixture of different (closely related and frequently Nano particulate) structures that cannot be isolated and fully quantitated, characterised, and/or described by physicochemical analytical methods. NBCDs are medicinal products but not biological medicines. Like biologics, the composition, quality, and in vivo performance of NBCDs are highly dependent on the manufacturing processes of the active ingredient, as well as (in most cases) the formulation.(A.^2,3; The word “NBCDs” is becoming more popular among scientists, despite neither the U.S. Food and Drug Administration (FDA) nor the European Medicines Agency (EMA) having formally acknowledged it^4–7 “Follow-on products” have been used to describe copy versions (e.g., by the EMA; the FDA and other agency includes them in the category of “complex generics”).

Here, we first go over the regulatory frameworks that are currently in place to assess whether biosimilar and NBCD follow-on products are equivalent, and then we go over the relevant quality, safety, and efficacy factors. We also discuss the necessity of regulatory alignment and stress the significance of identifying the features of products that guarantee their safety and effectiveness in humans (critical quality attributes). We discuss the points of consensus and remaining unresolved challenges and regulatory disparities existing among the United States, European Union & Latin America in the light of complex generics.

Materials and Methods

The United States of America

Two different legislation serve as the foundation for the FDA's drug regulation: The Food, Drug & Cosmetics Act for low molecular-weight drugs and generics and the Public Health Service Act for biologics and biosimilar (Figure 2(a)). The FDA has generated guidance documents for the development of biosimilar in the US and as of the end of 2016, four biosimilar products were approved for the U.S. market ⁸ The FDA did not adopt the term “NBCD” but uses the term “complex product” instead, which generally includes products with complex active ingredients, complex formulations, complex routes of delivery, complex dosage forms, complex drug–device combination products, or other products where complexity or uncertainty concerning the approval pathway—or a possible alternative approach—would benefit from early scientific engagement ⁹ These complex products, not being of biological origin, automatically fall under the Food, Drug & Cosmetics Act. According to this act, novel products are evaluated through the NDA (New Drug Application) regulatory pathway, while generics or copies are authorized through the ANDA (Abbreviated New Drug Application) regulatory pathway. A side-by-side comparison of the NDA and ANDA pathways shows that animal studies, clinical studies, and bioavailability studies required by the NDA pathway are replaced by BE testing in the ANDA pathway. After therapeutic equivalency (TE) to the original treatment is demonstrated on the basis of a PE and BE demonstration, generic pharmaceuticals are given marketing approval. The great majority of generic medications are completely described homo-molecular, low-molecular-weight substances. As a result, TE for such medications can be demonstrated rather easily. However there are scientific difficulties in proving PE and BE for complicated compounds to which the ANDA pathway applies, including the inability to synthesize homo-molecular material, an unknown mode of action, and/or the difficulty to fully characterize the products. This requires a stepwise comparison of the reference drug and the complex drug generic, and the FDA generally adopts a weight of-evidence approach. The amount of evidence that is required for the authorization of a certain complex drug product is evaluated by the FDA through a case-by-case approach. In support of this methodology, With regulatory science funding under the Generic Drug User Free Amendments (GDUFA), the FDA promotes research. low-molecular-weight heparin (LMWH ¹⁰ and glatiramer acetate (GA ¹¹ are two complex drugs that were approved by the FDA under the ANDA pathway. Per the FDA, equivalence across these four themes will ensure safety and efficacy in humans without the need for additional clinical trials. Interestingly, the fourth theme, confirmatory (biological) assays, shows an important difference in the approach to equivalence assessment between enoxaparin sodium and GA copies: while the FDA requires demonstration of statistical equivalence of pharmacodynamics parameters in humans for enoxaparin sodium, No human test is required; instead, the experimental autoimmune encephalomyelitis (EAE) animal model is advised.

OPEN IN VIEWER

Figure 2.

Schematic representation of the (a) USFDA, (b) EMA and (c) ANVISA & NIH approval pathways.

Discussion

The difficulties in creating, regulating, and bringing to patients biosimilars and NBCD follow-on versions are generally acknowledged by the scientific community. Important developments were reported at the meeting held on November 9, 2016, at the New York Academy of Sciences: all stakeholders agreed that complex drugs and their follow-ons should be evaluated with great care and that it is an absolute necessity to define the critical attributes in order to ensure safety and efficacy. Despite the fact that progress has been made in defining common ground, it is important to continue the discussions, especially since increasing numbers of complex products are under development, and the accessibility to generic, biosimilar, and/or follow-on versions has shown to play an important role in lowering the overall expenditure in health care ⁴⁹ In order to guarantee the provision of high-quality, safe, and effective biosimilar and NBCD follow-on products to patients in a timely fashion, there are a number of open issues that we, as a scientific community, have to address. We list the outstanding challenges here and hope that they may lead to actions to resolve them.

Conclusion

The term “complex hybrids,” which would provide a more suitable regulatory pathway for authorising Complicated generic follow-on products, has no legal definition. Regulatory authorities ought to take that route into consideration. Generic industries are highly interested in investing into the complex generic medicines since the future of these medicines in the marketplace is very bright. The dynamics of the fast-developing field of NBCD products pose significant challenges on how to regulate these products in an aligned and proportionate fashion. This study also raises the question on how to proceed giving the expected surge of follow-on NBCDs in the next decade. When looking at therapeutic equivalence and/or clinical comparability, data from specific clinical trials comparing the innovators and follow-on/similar products still seems to be the most prudent path. This prevents regulatory judgements based simply on preclinical evidence or straightforward physico-chemical characterization from falling into the trap of unexpectedly serious side effects or a lack of desired efficacy that, in most situations, cannot be entirely discounted. Therefore, we should always exclude any generic-like path in regulatory assessments during the pre-marketing evaluation of NBCDs. The most critical issues relate directly to the need for an appropriate frame for a decision-making procedure within the “real-life” clinical setting, when facing the choice between the innovator (original medicinal product) and its “similar” medicinal product. In fact, after regulatory clearance of generics, we are unable to implement the straightforward interchangeability decision for NBCDs. Under the current system, the use of product-class arbitration to harmonize existing products in the market could be an option, but one with major uncertainty on the final outcome. Two complementary methods are needed to change the requirement to protect the patient from higher risks: (i) the regulatory processes being improved and their guidance documents in the pre-registration phase, recognizing that regulators should step in with improved regulatory guidance and better clarification of procedures; and (ii) whenever comparative clinical data is still not available (provided by appropriately designed clinical trials), the need for adequate safety and efficacy data—if interchangeability is to be considered—might also include appropriate post marketing risk management programmes, depending on a risk appraisal that has to be considered for each individual product, based only on the nature of the submitted relevant set of safety/efficacy data. When regulatory authorities, together, deduce the challenges, studies required and approval basis of complex medicines, only then the patients will have adequate access to safe and cost-effective complex generics.